Table 2.
Clinical data summary
| GEO ID | Median age |
Median size (cm) |
Lymph node status | Chemo-therapy info. | Hormone treatment info. | ER status | HER2 status | PR status | Tumour grade (1/2/3) | DFS (months) | DDFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSE7849 | 55 ± 12 | 2.3 ± 1.1 | A | A | A | A | NA | A | 2/30/34 | 81 ± 40 | NA | NA |
| GSE3143 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 51 ± 31 | NA | A |
| GSE12276 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 26 ± 22 | NA | NA |
| GSE22219 | 55 ± 11 | 2.6 ± 1.4 | A | NA | NA | A | NA | NA | 41/87/63 | 94 ± 38 | NA | NA |
| GSE10510 | 59 ± 12 | NA | A | NA | NA | A | NA | A | NA | 57 ± 53 | NA | 87 ± 60 |
| NKI295, (Chang et al., 2005) | 44 ± 5 | 2.25 ± 0.9 | A | A | NA | A | NA | NA | NA | 84 ± 50 | NA | 94 ± 47 |
| Chin et al., 2006 | 55 ± 15 | 2.7 ± 1.4 | A | A | A | A | A | A | 10/42/61 | NA | 69 ± 48 | NA |
| GSE9893 | 67 ± 10 | 2.3 ± 0.9 | A | NA | A | A | NA | NA | 21/94/33 | 65 ± 32 | 66 ± 31 | 72 ± 29 |
| GSE7390 | 46 ± 7 | 2.2 ± 0.8 | NA | NA | NA | A | NA | NA | 30/83/83 | 113 ± 68 | 114 ± 65 | 138 ± 61 |
| GSE16391 | 62 ± 8 | NA | A | A | A | A | A | A | NA | 35 ± 15 | NA | NA |
| GSE25055 | 49 ± 10 | NA | A | A | A | A | A | A | 32/180/259 | NA | 36 ± 20 | NA |
| GSE24450 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 72 ± 27 |
| GSE1992 | 55 ± 15 | NA | A | NA | NA | A | NA | NA | 8/34/57 | 25 ± 23 | NA | 29 ± 25 |
| GSE20685 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 88 ± 43 | 94 ± 38 |
| Kok et al., 2009 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 15 ± 17 | NA | NA |
| GSE9195 | 64 ± 9 | 2.4 ± 0.96 | A | NA | A | A | NA | A | 14/20/24 | 95 ± 30 | 97 ± 28 | NA |
| GSE6532 | 59 ± 13 | 2.2 ± 0.9 | A | NA | A | A | NA | A | 38/71/24 | 71 ± 42 | 71 ± 42 | NA |
| GSE1378, GSE1379 | 67 ± 9 | 2.3 ± 1.1 | A | NA | NA | A | A | A | 3/39/18 | 87 ± 46 | NA | NA |
| GSE3494 | 62 ± 13 | 2.3 ± 1.25 | A | NA | NA | A | NA | A | 67/128/54 | NA | NA | 98 ± 46 |
| GSE45255 | 55 ± 12 | 2.9 ± 1.3 | A | A | A | A | A | A | 17/52/67 | 48 ± 22 | 51 ± 25 | 54 ± 21 |
| GSE1456 | NA | NA | NA | NA | NA | NA | NA | NA | 28/58/61 | 72 ± 29 | NA | 77 ± 23 |
| GSE21653 | 54 ± 14 | NA | A | NA | NA | A | A | A | 45/89/125 | 60 ± 41 | NA | NA |
| GSE17907 | 50 ± 14 | NA | A | NA | NA | A | A | A | 3/10/34 | 39 ± 29 | NA | NA |
| GSE11121 | NA | 2 ± 0.99 | A | NA | NA | NA | NA | NA | 29/136/35 | NA | 94 ± 51 | NA |
| GSE2034 | NA | NA | A | NA | NA | A | NA | NA | NA | 78 ± 42 | NA | NA |
| GSE12093 | NA | NA | A | A | A | A | NA | NA | NA | 92 ± 38 | NA | NA |
A, available; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2' PR, progesterone receptor; DFS, disease free survival; DDFS, distant disease free survival; NA, not available; OS, overall survival; tumour grade (1/2/3), 1 refers to number of grade 1 tumours, 2 refers to the number of grade 2 tumours and 3 refers to the number of grade 3 tumours.